Literature DB >> 19935145

Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy.

Aimee W Kao1, Caroline A Racine, Lovingly C Quitania, Joel H Kramer, Chadwick W Christine, Bruce L Miller.   

Abstract

Parkinson disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) share alpha-synuclein immunoreactivity. These "synucleinopathies" have overlapping signs and symptoms, but less is known about similarities and differences in their cognitive and neuropsychiatric profiles. We compared the cognitive and neuropsychiatric profiles of individuals with PD, MSA, and DLB. Overall, the DLB group showed the most cognitive impairment, the MSA group demonstrated milder impairment, and the PD group was the least cognitively impaired. The DLB and MSA groups showed worse executive function and visuospatial skills than PD, whereas DLB showed impaired memory relative to both PD and MSA. On the neuropsychiatric screening, all groups endorsed depression and anxiety; the DLB group alone endorsed delusions and disinhibition. Consistent with their greater level of cognitive and neuropsychiatric impairment, the DLB group showed the greatest amount of functional impairment on a measure of instrumental activities of daily living (Functional Activities Questionnaire). We found that MSA subjects had cognitive difficulties that fell between the mild deficits of the PD group and the more severe deficits of the DLB group. PD, MSA, and DLB groups have similar neuropsychiatric profiles of increased depression and anxiety. Similar underlying alpha-synuclein pathology may contribute to these shared features.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935145      PMCID: PMC2886667          DOI: 10.1097/WAD.0b013e3181b5065d

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  37 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Alpha-synuclein: normal function and role in neurodegenerative diseases.

Authors:  Erin H Norris; Benoit I Giasson; Virginia M-Y Lee
Journal:  Curr Top Dev Biol       Date:  2004       Impact factor: 4.897

3.  Identification of brain disorders by the Stroop Color and Word Test.

Authors:  C J Golden
Journal:  J Clin Psychol       Date:  1976-07

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Cognitive and motor performance in multiple system atrophy and Parkinson's disease compared.

Authors:  D Testa; V Fetoni; P Soliveri; M Musicco; E Palazzini; F Girotti
Journal:  Neuropsychologia       Date:  1993-02       Impact factor: 3.139

6.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

Review 7.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

8.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD.

Authors:  D W Dickson; D Ruan; H Crystal; M H Mark; P Davies; Y Kress; S H Yen
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

9.  The neuropsychological profile in dementia with Lewy bodies and Alzheimer's disease.

Authors:  Haruhiko Oda; Yasuji Yamamoto; Kiyoshi Maeda
Journal:  Int J Geriatr Psychiatry       Date:  2009-02       Impact factor: 3.485

View more
  40 in total

Review 1.  Diagnosis and differential diagnosis of MSA: boundary issues.

Authors:  Han-Joon Kim; Beom S Jeon; Kurt A Jellinger
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

Review 2.  Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.

Authors:  Iva Stankovic; Florian Krismer; Aleksandar Jesic; Angelo Antonini; Thomas Benke; Richard G Brown; David J Burn; Janice L Holton; Horacio Kaufmann; Vladimir S Kostic; Helen Ling; Wassilios G Meissner; Werner Poewe; Marija Semnic; Klaus Seppi; Atsushi Takeda; Daniel Weintraub; Gregor K Wenning
Journal:  Mov Disord       Date:  2014-04-18       Impact factor: 10.338

Review 3.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 4.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

5.  The association of SNCA with hazardous alcohol use is mediated by impulsivity.

Authors:  Casey R Guillot; Raina D Pang; Adam M Leventhal; Tiebing Liang; Mitchell E Berman
Journal:  Psychiatry Res       Date:  2015-02-24       Impact factor: 3.222

Review 6.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

Review 7.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 8.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

Review 9.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

10.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.